All In Biotech

Drug Trial Radar · NCT06188520

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

A Phase I/IIa, First-in-human, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

55

Actual

Start

Dec 5, 2023

Primary completion

Jun 30, 2027

Study completion Jun 30, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jan 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to evaluate AZD8421 alone and in combination with selected targeted anti-cancer drugs in patients with ER+HER2- advanced breast cancer, and patients with metastatic high-grade serious ovarian cancer.

Conditions

  • ER+ HER2- Advanced Breast Cancer
  • High-grade Serous Ovarian Cancer (HGSOC)

Interventions

  • AZD8421Drug

    CDK2 inhibitor

  • CamizestrantDrug

    SERD

  • RibociclibDrug

    CDK4/6 inhibitor

  • PalbociclibDrug

    CDK4/6 inhibitor

  • AbemaciclibDrug

    CDK4/6 inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose limiting toxicities (DLTs) as defined in the protocol.Time frame: From start of treatment until the end of DLT period, assessed up to 28 days.
  2. Incidence of AEs/SAEsTime frame: From start of treatment until the end of safety follow-up, approximately 18 months.
  3. Clinically significant changes from baseline in clinical laboratory parameters, vital signs and ECGs.Time frame: From start of treatment until the end of safety follow-up, approximately 18 months.
  4. Discontinuation of AZD8421 due to toxicityTime frame: From start of treatment until the end of safety follow-up, approximately 18 months.

Locations

13 sites in 5 countries. Site status is shown where the registry gives one.

  • Research Site

    St Louis, Missouri

  • Research Site

    Providence, Rhode Island

  • Research Site

    Nashville, Tennessee

  • Research Site

    Houston, Texas

  • Research Site

    East Melbourne, Australia

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Barcelona, Spain

  • Research Site

    Pamplona, Spain

  • Research Site

    Valencia, Spain

  • Research Site

    Cambridge, United Kingdom

  • Research Site

    London, United Kingdom

  • Research Site

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.